Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIE trial of lenvatinib plus ifosfamide/etoposide versus ifosfamide/etoposide in relapsed or refractory osteosarcoma
NL-OMON49371Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in osteosarcoma (OS) comparing Lenvatinib + Ifosfamide + Etoposide with Ifosfamide + Etoposide (2 arms). Primary endpoint: Progression-free survival by independent imaging review. Started Jul 2021; status: completed.
02
Drugs
lenvatinibifosfamideetoposide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NL-OMON49371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49371.